ANIP
ANI Pharmaceuticals Posts Strong First Quarter 2026 Results, Raises Financial Guidance
Ani Pharmaceuticals, Inc. reported a robust first quarter 2026 performance, driven by strong growth across its rare disease and generics businesses. The company's total net revenues increased 20% year-over-year to $275.1 million, while adjusted EBITDA grew 24% to $71.4 million. The company cited the success of